Valuation: Celsion Corporation

Market Cap 7.9M 6.94M 6.38M 5.95M 11.22M 751M 11.45M 76.79M 29.75M 369M 29.66M 29.02M 1.28B P/E 2026 *
-0.6x
P/E 2027 * -0.83x
Enterprise Value 7.9M 6.94M 6.38M 5.95M 11.22M 751M 11.45M 76.79M 29.75M 369M 29.66M 29.02M 1.28B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.24%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%+3.38%+72.77%+131.31% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.93%+4.11%-12.64%-12.98% 23.75B
+0.36%+3.42%+9.61%+407.11% 23.19B
+3.64%+8.34%+39.81%-5.88% 18.14B
+1.03%+5.55%+40.16%-29.95% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.20%+13.33%+42.13% - 12.97B
Average +1.89%+6.94%+51.95%+139.68% 26.21B
Weighted average by Cap. +1.58%+6.60%+56.47%+132.01%

Financials

2026 *2027 *
Net sales - -
Net income -16.41M -14.41M -13.26M -12.36M -23.3M -1.56B -23.78M -159M -61.79M -766M -61.61M -60.27M -2.66B -23.33M -20.48M -18.85M -17.57M -33.13M -2.22B -33.8M -227M -87.85M -1.09B -87.59M -85.69M -3.79B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-